ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
Initiative
ESG Report
IR
Stock Index
Official Notice
PR
Press
Library
CAREERS
Recruiting
ENG
Korean
English
home
Title + Content
Title+Content
Title
Content
Search
Number
Title
Author
Date
108
HLB’s rivoceranib proven effective in esophageal cancer
admin
2022.07.21
107
Rivoceranib’s combined clinical results will be known at IASLC 2022: HLB
admin
2022.07.15
106
HLB gets positive Phase 3 data with liver cancer treatment
admin
2022.05.16
105
Elevar Therapeutics to announce Phase 2 Results of Rivoceranib on ACC at ASCO
admin
2022.04.29
104
Immunomic Therapeutics approaches First-In-Human Trial for Merkel Cell Carcinoma
admin
2022.04.28
103
HLB posts earnings surprise in Q1
admin
2022.04.26
102
AACR reveals a 'Real-World Data' of Rivoceranib's Efficacy and safety in HCC
admin
2022.04.11
101
HLB leads social responsibility management by joining UNGC
admin
2022.03.16
100
Elevar Therapeutics Announces Key Management changes
admin
2022.03.15
99
HLB receives first Rivoceranib royalty from Chinese Hengrui Pharmaceutical
admin
2022.03.08
1
2
3
4
5
6
7
8
9
10
>
>>